Results 111 to 120 of about 8,834,434 (252)

Buprenorphine: a new alternative in the treatment of opioid addiction

Psychiatry and Clinical Psychopharmacology, 2021
Opioid addiction is a complex disease with severe biological, psychological, and social impacts in the life of the individual, his family and the society. Besides heroin, misuse and abuse of prescription opioid pain medications are rising.
Tahir Tellioglu
doaj  

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

The impact of harm reduction interventions on injection‐related bacterial infections among people who inject drugs: A systematic review

Addiction, EarlyView.
Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien, Lobna Tijani, Nadia Hachicha, Manon Godart, Mathieu Castry, Karen Champenois, Perrine Roux, Sylvie Deuffic‐Burban   +7 more
wiley   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Informed Consent To Opioid Agonist Maintenance Treatment: Recommended Ethical Guidelines

, 2008
BACKGROUND: Some bioethicists have questioned whether opioid addicted individuals are able to provide free and informed consent to opioid agonist maintenance treatment. Conflicting motives for providing such treatment (e.g.
Hall, Wayne, Carter, Adrian, Adrian Carter, Wayne Hall   +3 more
core   +1 more source

Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada

Addiction, EarlyView.
Abstract Background and aims In 2020, British Columbia (BC), Canada, introduced ‘Prescribed Alternatives’ (PA) as an approach to offering regulated substances to people accessing the unregulated supply. This study aimed to estimate and compare prescribing characteristics of dextroamphetamine and methylphenidate stimulant PAs in BC, to estimate ...
Bin Zhao, Kevin Hu, Roshni Desai, Shania Au, Kali‐olt Sedgemore, Vitor Tardelli, Addie Carter, Paxton Bach, Christian Schutz, Amanda Slaunwhite, Alexis Crabtree, Heather Palis   +11 more
wiley   +1 more source

Social trauma and the mu-opioid system in depression [PDF]

, 2011
The overarching thesis under investigation is that the endogenous opioid system plays a key role in depression subsequent to traumatic childhood social experiences. This is suggested by the fact that animal work indicates that mu-opioids robustly mediate
Malcolm-Smith, Susan
core  

Opioid Medical Detoxification Compared to Opioid Agonist Treatment during Pregnancy: A Scoping Review [PDF]

Opioid use disorder (OUD) is highly prevalent, affecting up to 1% of pregnancies. The current standard of care for the management of OUD during pregnancy has been maintained with opioid agonist treatment (OAT), using either methadone or buprenorphine ...
Ordean, Alice, Isabella DeVuono, DeVuono, Isabella, Alice Ordean   +3 more
core   +1 more source

Clinicians' and people who use drugs' perspectives on artificial intelligence in addiction medicine

Addiction, EarlyView.
Abstract Background and aims Artificial intelligence (AI) may improve addiction medicine workflows and health outcomes but raises questions about data privacy and unintended harms for people who use drugs (PWUD). This qualitative study aimed to understand the perspectives of clinicians and PWUD regarding perceived benefits and concerns about clinical ...
Patrick J. A. Kelly, Elizabeth Chen, Amelia Bailey, Katie Biello, Brandon D. L. Marshall, Josiah D. Rich, Jaclyn M. W. Hughto   +6 more
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Addiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke, Johan Duflou, Agata Chrzanowska, Michael Farrell, Julia Lappin, Amy Peacock   +5 more
wiley   +1 more source